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Bidirectional vesicular transport between the endo-
plasmic reticulum (ER) and Golgi is mediated largely
by ARF and Rab GTPases, which orchestrate vesicle
fission and fusion, respectively. How their activities
are coordinated in order to define the successive
steps of the secretory pathway and preserve traffic
directionality is not well understood in part due to
the scarcity of molecular tools that simultaneously
target ARF and Rab signaling. Here, we take advan-
tage of the unique scaffolding properties of E. coli
secreted protein G (EspG) to describe the critical
role of ARF1/Rab1 spatiotemporal coordination in
vesicular transport at the ER-Golgi intermediate
compartment. Structural modeling and cellular
studies show that EspG induces bidirectional traffic
arrest by tethering vesicles through select ARF1-
GTP/effector complexes and local inactivation of
Rab1. The mechanistic insights presented here
establish the effectiveness of a small bacterial cata-
lytic scaffold for studying complex processes and
reveal an alternative mechanism of immune regula-
tion by an important human pathogen.
INTRODUCTION
Membrane-associated pattern recognition receptors (PRRs),
including Toll-like receptors, NOD-like receptors, RIGI recep-
tors, and C-type lectins, recognize bacterial and viral pathogens
and induce the expression of cytokines and chemokines that
amplify the inflammatory response (Takeuchi and Akira, 2010).
Although this system is highly effective in combating a diverse
range of microbes, many bacterial pathogens have evolved stra-
tegies to overcome host defenses. In particular, Gram-negative
bacteria use dedicated molecular machinery (e.g., type III secre-
tion systems) that allows translocation of ‘‘effector proteins’’ into
host cell cytoplasm (Gala´n and Collmer, 1999; Gala´n and Wolf-
Watz, 2006). These molecules can covalently modify host
signaling enzymes or directly mimic their regulatory components878 Cell Reports 6, 878–891, March 13, 2014 ª2014 The Authors(Alto and Orth, 2012). Research over the past decade has
focused primarily on identifying bacterial effector proteins that
inhibit signal transduction cascades stimulated by the activation
of PRRs (Baxt et al., 2013; Espinosa and Alfano, 2004). In
contrast, only recently have researchers attempted to identify
bacterial mechanisms that prevent cytokine and chemokine
secretion by inhibiting vesicular transport through the general
secretory pathway (GSP) (Burnaevskiy et al., 2013; Clements
et al., 2011; Dong et al., 2012; Selyunin et al., 2011). Although
arrest of protein transport would disable a wide variety of
immune signaling pathways and therefore seems highly advan-
tageous for pathogens, this strategy presents a challenge for
bacteria that rely on host resources for survival (i.e., intracellular
pathogens) and thus must be carefully orchestrated.
Cargo transport through the GSP follows a concerted route
that includes the endoplasmic reticulum (ER), ER-Golgi inter-
mediate compartment (ERGIC), and the Golgi apparatus. The
packaging and delivery of transport vesicles between these
compartments depends on microtubules and golgins, which
control trafficking infrastructure and structural organization,
and the function of ARF- and Rab-family GTPases, which play
essential roles in regulating coat protein recruitment and
budding, as well as tethering and fusion with target membranes,
respectively (Donaldson and Jackson, 2011; Hutagalung and
Novick, 2011). Like other members of the Ras superfamily,
ARFs and Rabs cycle between active GTP-bound and inactive
GDP-bound conformations. Exchange of GDP for GTP is medi-
ated by guanine-nucleotide exchange factors (GEFs), whereas
GTPase activating proteins (GAPs) stimulate hydrolysis of GTP
to GDP (Cherfils and Zeghouf, 2013). In their active state, spe-
cific interactions of ARF and Rab GTPases with their down-
stream substrates define the molecular sequence of events
that coordinate specific membrane trafficking events. Because
the rapid turnover of GTPase signaling networks is essential for
receptor localization and cytokine secretion, microbial regulation
of host GTPases and their downstream interactions may be a
powerful mechanism of immune evasion.
Recently, we discovered that the enterohemorrhagic E. coli
(EHEC) type III bacterial effector protein EspG interacts directly
with the GTP-active form of ARF1 and inhibits GAP-stimulated
GTP hydrolysis (Selyunin et al., 2011). In addition, we found
that EspG stimulated p21-activated kinase (PAK) through a
nonoverlapping protein surface adjacent to the ARF1-binding
site (Selyunin et al., 2011). In subsequent studies, Dong et al.
(2012) showed that EspG functions as a Rab1-specific GAP
through an endogenous TBC-like mechanism of action, despite
having a unique structural fold. Interestingly, similar to what was
observed for ARF1/PAK binding, EspG can simultaneously
interact with ARF1 and Rab1. Together, these findings revealed
a strong mechanistic connection underlying simultaneous
recognition of multiple host proteins by EspG, and suggested
that the scaffolding properties of a bacterial effector protein
may allow selective control over signaling pathways at the Golgi
apparatus. However, the significance of GTPase coupling
through scaffolding properties has never been directly tested
and the molecular mechanism of membrane trafficking regula-
tion by EspG remains elusive. Considering the critical role of
the GSP in innate immune function, we sought to delineate the
biochemical significance behind simultaneous targeting of
ARF1 and Rab1 signaling by EspG.
Here, we describe a model in which EspG arrests vesicular
transport by stabilizing the ARF1-GTP tethering complex with
simultaneous local inhibition of Rab1 signaling. By preventing
GAP-mediated cycling of ARF1-GTP, EspG promotes the
recruitment of ARF1-dependent tethering factors that restrict
vesicle movement, whereas the Rab1-GAP activity of EspG
further inhibits intracellular trafficking by preventing vesicle
fusion. Importantly, we show that the scaffolding properties
that allow simultaneous activity of EspG toward ARF1 and
Rab1 GTPases are required for full potency during arrest of
host intracellular trafficking.
RESULTS
EspG Disrupts Golgi through a Unique GTPase
Regulatory Mechanism
The framework for understanding regulation of the GSP by ARF
and Rab GTPases was previously established by studying
cellular phenotypes resulting from their inactivation. In particular,
our knowledge about ARF1 function in ER and Golgi trafficking
was aided by the discovery of Brefeldin A (BFA), a fungal toxin
that inhibits vesicle budding and transport by stabilizing an
ARF1-GDP/GEF complex and preventing its transition into an
active state (Klausner et al., 1992; Mossessova et al., 2003).
Analogously, the roles of Rab1 signaling in membrane transport
have been extensively studied using inhibition by GAPs and
dominant-negative constructs (Haas et al., 2007). Importantly,
inactivation of ARF1 or Rab1 signaling induces severe trafficking
defects due to an arrest of ER export of proteins, manifested by
accumulation of Golgi enzymes in the ER (Haas et al., 2007;
Lippincott-Schwartz et al., 1989). However, the gross pheno-
typic changes associated with inactivation of an entire GTPase
pathway by this method makes it difficult to understand the
details of the numerous protein interactions that regulate Golgi
function. In addition, because this approach targets individual
pathways, it is not effective for elucidating the potential coordi-
nation of ARF1 and Rab1 signaling systems.
Detailed examination of a single bacterial effector molecule in
the context of microbial infection has so far proven difficult, since
type III secretion systems can deliver multiple effector proteins atany given time (Gala´n and Collmer, 1999). To overcome the
problems associated with this complex system, we used micro-
injection of purified recombinant protein, which allowed us to
focus exclusively on the effects of EspG under physiologically
relevant concentrations. When microinjected into cells, EspG
induced fragmentation of the perinuclear Golgi ribbon and
caused swelling of the ER-Golgi Intermediate Compartment
(ERGIC), a complex system of tubulovesicular membrane clus-
ters found near ER exit sites (Figure S1A). Considering that
EspG arrests ARF1 GTP cycling (Selyunin et al., 2011) and
displays Rab1-GAP activity (Dong et al., 2012), we set out to
determine whether EspG functions by blocking ER export anal-
ogously to BFA and overexpression of eukaryotic Rab1-GAPs,
or whether there exist important mechanistic differences
between EspG and these independent GTPase inhibitors.
To accurately address the effects of EspG on ER export,
we developed a technique that tracks the movement of
fluorescently labeled resident trans-Golgi enzyme b-1,4-galacto-
syltransferase (GalT) through the secretory network, thus mini-
mizing off-target effects, such as those associated with classic
temperature-shift assays (Presley et al., 1997). The protein
segment responsible for ER export and Golgi retention of GalT
(residues 1–81) was translationally fused to the conditional
aggregation domain (CAD) of a ligand-reversible crosslinking
protein, FKBP F36M (Rivera et al., 2000), producing a marker
we termed Golgi-CAD (Figure 1A). When transfected into cells,
Golgi-CAD aggregated and was retained in the ER (Figure 1B,
left). Addition of the small molecule AP21998 to the cell culture
medium relieved aggregation and initiated normal trafficking of
Golgi-CAD from the ER to the Golgi apparatus (Figure 1B, right).
To establish that the secretory pathway behaves normally
under these conditions, Golgi-CAD was first allowed to accu-
mulate in the ER, and then cells were treated with BFA for
30 min. AP21998 was added and Golgi-CAD localization was
assessed after 2 hr. As expected, BFA potently inhibited ER
export of Golgi CAD. Then, to determine whether EspG functions
similarly, cells expressing Golgi-CAD were microinjected with
EspG protein for 1 hr prior to AP21998 addition. Surprisingly,
Golgi-CAD successfully exited the ER in EspG-injected cells
but was arrested near vesicular clusters positive for p58, a
marker associated with ERGIC (Figure 1C). These data indicate
that EspG does not directly mimic the inhibitory mechanisms
of BFA, as shown here, or overexpression of Rab1-GAP, as
demonstrated previously (Haas et al., 2007). This notion was
confirmed by additional studies on the medial Golgi enzyme
N-acetylglucosaminyltransferase I (NAGT I) (Figure S1B).
EspG Induces Trafficking Arrest Phenotypes Similar to
Microtubule Disruption
Because EspG neither inhibited ER export nor induced accumu-
lation of Golgi enzymes in the ER, we sought to define additional
host factors that could complement its GTPase regulatory activ-
ities. In particular, EspG has been implicated in connection with
host microtubules (Matsuzawa et al., 2004), which serve as
tracks for vesicular transport (Cole et al., 1996). To examine
the extent of this potential connection, we compared the
distribution of cellular markers in cells treated with either EspG
or nocodazole, a small-molecule inhibitor of microtubuleCell Reports 6, 878–891, March 13, 2014 ª2014 The Authors 879
Figure 1. EspG Does Not Interfere with
Protein Export from the ER
(A) Schematic representation of the Golgi-CAD
construct design. Aggregation of Golgi-CAD is
mediated by FKBP F36M domains and can be
reversed by addition of AP21998 molecule.
(B) Development and confirmation of the inducible
ER-to-Golgi trafficking assay to study protein
transport through the early secretory pathway.
The trans-Golgi-associated marker (Golgi-CAD) is
trapped in the ER upon transfection (left), but is
trafficked to the Golgi after the addition of the small
molecule AP21998 (right).
(C) Fluorescent micrographs show the final
localization of Golgi-CAD 2 hr after addition of
AP21998. Golgi-CAD escapes the ER but is
arrested near p58-positive clusters (arrowheads) in
cells microinjected with EspG (asterisks). No ER
export occurs in cells treated with BFA.
See also Figure S1.polymerization. Nocodazole induced the redistribution of cis-
(GM130), medial- (NAGT I), and trans-Golgi (TGN46) markers in
a manner remarkably similar to that observed for EspG (Fig-
ure 2A). More importantly, during a Golgi-CAD trafficking assay,880 Cell Reports 6, 878–891, March 13, 2014 ª2014 The Authorsneither nocodazole nor EspG treatment
blocked ER export, but instead arrested
Golgi-CAD trafficking at the ERGIC, re-
sulting in enlarged p58-positive clusters
(Figure 2B). Surprisingly, however, no
distinguishable defect in the microtubule
network was found in cells microinjected
with EspG, despite fragmented Golgi (Fig-
ure 2C). Thus, EspG appears to mimic the
cellular effects of nocodazole by inhibiting
membrane transport, albeit through a
mechanism that is independent of the
microtubule network.
To further investigate the extent of
similarity between the EspG function
and microtubule-dependent processes,
we examined retrograde membrane trans-
port from the Golgi to the ER. This step of
retrograde transport can be readily studied
in cells treated with BFA, which induces
the formation of long Golgi membrane-
tubules along microtubule tracks that
rapidly fuse with ER membranes (Sciaky
et al., 1997). Normally, Golgi tubulation
and fusion are complete within 5–10 min
of BFA addition. We took advantage of
this phenotype to determine whether
EspG could arrest retrograde trafficking
of Golgi tubules. Cells were stimulated
with BFA (to induce tubulation) and simul-
taneously microinjected with EspG.
Remarkably, Golgi tubules that normally
disappear within minutes of BFA treatment
were instead completely arrested in thepresence of EspG, and persisted even after 1 hr posttreatment
(Figure 2D). Importantly, further cellular observations confirmed
that these tubules extended from the cis-Golgi (Figure 2E).
Because it is unlikely that the EspG family of proteins directly
Figure 2. EspG Functionally Mimics Disruption of Microtubule-Dependent Processes
(A) Fluorescent micrographs show Golgi morphology relative to positioning of cis- (GM130), medial- (NAGT I), and trans-Golgi (TGN46) markers in cells treated
with nocodazole or microinjected with EspG.
(B) Nocodazole prevents Golgi-CAD transport at p58-positive clusters during the inducible trafficking assay in a manner analogous to that observed for EspG.
(C) EspG shows no apparent defect inmicrotubule network, despite the similar presentation of Golgi phenotypes.Microinjected cells aremarked with an asterisk.
(D) BFA-induced Golgi tubules persist in EspG-injected cells and fail to fuse with ER, suggesting inhibition of membrane transport along microtubules.
Microinjected cells are marked with an asterisk.
(E) Persistent BFA-induced Golgi tubules (green) emerge from and connect cis-Golgi (GM130, red) in cells transfected with EspG (asterisks).
See also Figure S3.binds (Germane et al., 2008) or depolymerizes microtubules
(shown in Figure 2C), we hypothesized that its mechanism is
therefore dependent on the unusual properties manifested
through simultaneous interactions with multiple host targets.
Specifically, we focused on its binding to ARF1 and Rab1,
considering their critical roles in ER-to-Golgi traffic and particu-
larly their connection to microtubule-dependent cellular events
(Horgan and McCaffrey, 2011).
Structural Separation of ARF1 and Rab1 Regulatory
Functions of EspG
Although both structural and biochemical interaction data
support the simultaneous binding of ARF1 and Rab1 to EspG
(Dong et al., 2012), the relative contribution of each interaction
to Golgi fragmentation and/or coordination with microtubule
processes is unknown. To dissect their functional roles, we first
generated EspG mutants that lacked either ARF1 binding or
Rab1-GAP activity (Figure 3A). After a detailed analysis ofavailable structural data and systematic mutagenesis, we identi-
fied an EspG mutant, I152S/P351A/P355A (EspG IPP), that was
unable to bind ARF1 (Figure 3B) but retained potent GAP activity
toward Rab1 (Figure 3C). Additionally, mutations in catalytic
residues Arg-208 and Gln-293, which are required for EspG to
function as a Rab1-GAP (Dong et al., 2012), had no defect in
ARF1-GTP binding (Figures 3B and 3C).
Having created mutants specific for individual GTPases, we
next compared their ability to produce changes in Golgi ribbon
morphology and alter the appearance of p58-positive clusters
to wild-type (WT) EspG protein. To accurately quantify this
phenotype, we defined Golgi fragmentation as a relative spread
of outermost Golgi marker appearance that exceeded 3 SDs
from the spread measured in uninjected cells of the same exper-
iment (Figure S2). Even at low cellular concentrations of protein,
EspG WT induced Golgi disassembly and enlarged ERGIC in
virtually every cell (100%; Figures 3D and 3E). In contrast, the
ARF1-binding-deficient mutant, EspG IPP, did not disrupt GolgiCell Reports 6, 878–891, March 13, 2014 ª2014 The Authors 881
Figure 3. Separating the Roles of ARF1 and Rab1 in the EspG Mechanism
(A) Identification of predicted ARF1- and Rab1-specific functional mutants based on structural data of EspG bound to ARF and Rab GTPases (3PCR, 4FMC, and
4FME). Mutations are shown in red, and blue spheres denote water molecules.
(B) Pull-down experiments testing the ability of EspG mutants to bind ARF1.
(C) Rab1-GAP assay testing the GAP activity of EspG constructs.
(D) Golgi disassembly by EspG deficient for either ARF1 binding or Rab1-GAP activity as determined by Golgi ribbon fragmentation and enlarged p58 clusters.
Representative micrographs are shown for the lowest and highest concentrations tested. Microinjected cells are marked with an asterisk.
(E) Quantification of disrupted Golgi and p58 clusters phenotype. Needle concentrations are shown.
See also Figures S2 and S3.architecture at any concentration tested (2.8% ± 0.3%), despite
its ability to function as a Rab1 GAP (Figures 3D and S3). The
cellular Rab1-GAP function of EspG may therefore require asso-
ciation with ARFGTPase in order tomanifest the Golgi disruption
phenotype. In agreement with this coordination of activities, the
EspG RQmutant, which was deficient for Rab1-GAP properties,
induced Golgi fragmentation with significantly less potency than
EspG WT (Figures 3D and 3E). However, increasing the concen-
tration of microinjected EspG RQ resulted in an increase in the
number of cells with fragmented Golgi (Figure 3E), suggesting
that higher levels of ARF1 binding could compensate for the
absence of its Rab1-GAP activity.
EspG Disruption of Golgi Morphology Is PAK
Independent
In addition to its ARF1-binding and Rab1-GAP properties, EspG
directly stimulates PAK kinase activity (Selyunin et al., 2011).
Interestingly, the binding sites for PAK and Rab1 share the
same surface on EspG, suggesting that only one of the targets
can bind at a time (Figure 4A). Therefore, regulatory scaffolding
that is at the core of the EspG mechanism of Golgi disassembly
could also involve ARF1/PAK complex. To address the role of
PAK, we looked at the ability of EspG to induce Golgi fragmenta-
tion in the absence of PAK activity. When we tested EspG
constructs for interaction with PAK autoinhibitory domain (AID;882 Cell Reports 6, 878–891, March 13, 2014 ª2014 The Authorsresidues 1–241), we found that the WT and RQ mutants could
effectively interact with PAK, whereas the ARF1-binding-
deficient EspG IPP could not (Figure 4B). We were unable to
isolate EspG mutants that were deficient for PAK activation,
but not for ARF1 binding, likely due to linked structural features
(Selyunin et al., 2011; A.S.S. and N.M.A., unpublished data).
Thus, we could not address the roles of PAK versus Rab1 in
EspG function using binding-specific mutants.
To overcome this difficulty, we used a PAK-specific small-
molecule inhibitor (IPA-3) to globally inhibit PAK activity (Deacon
et al., 2008). First, we confirmed that the EspG mechanism of
PAK activation is sensitive to IPA-3 treatment. We found that
EspG is susceptible to IPA-3 inhibition, even to a greater extent
than observed for Cdc42 (IC50 = 0.3 mMand 0.6 mM, respectively;
Figure 4C). Next, cells were either microinjected with EspG/IPA-
3 (50 mM) mix or incubated overnight in media containing 20 mM
IPA-3 and then microinjected with EspG for 1 hr. In both cases,
IPA-3 treatment had no effect on the ability of EspG to induce
Golgi disassembly (Figures 4D and 4E). From these observa-
tions, we conclude that the ARF1-binding and Rab1-GAP activ-
ities of EspG, rather than PAK activation, that are responsible for
disrupting the Golgi morphology. Taken together, our data indi-
cate that cooperation between ARF1 and Rab1 signaling is
required for full potency of EspG, and establish the EspG interac-
tion with ARF1 as a key regulatory point in the EspGmechanism.
Figure 4. Fragmentation of the Golgi by EspG Is PAK Independent
(A) PAK and Rab1 share the binding surface on EspG. Protein Data Bank structures 3PCS and 4FME were used for alignment.
(B) Binding of EspG constructs to PAK AID. The ARF1-binding deficient mutant (IPP) does not interact with PAK.
(C) Kinase assay showing the sensitivity of PAK activation to IPA-3. Radiography data from the assays were quantified and plotted to determine IC50 values.
(D and E) Golgi fragmentation is induced by EspG in cells treated with IPA-3 to inhibit PAK. Microinjected cells are marked with an asterisk.EspG Functions Primarily through an ARF1 Signaling
Axis
In previous structural studies, we found that EspG occludes
ARFGAP access to the GTP binding pocket of ARF1 by interact-
ing at a distal site of the Switch I loop (Selyunin et al., 2011). Inter-estingly, this unusual binding architecture is distinct from known
endogenous ARF1 substrate interactions, which primarily
associate through the Switch II and b2/3 interswitch region
(Nie et al., 2003). Thus, in addition to locking ARF in the GTP-
active state, EspG may drive ARF1-GTP interactions withCell Reports 6, 878–891, March 13, 2014 ª2014 The Authors 883
specific downstream substrates. Structural modeling revealed
that EspG has no steric interference with the GAT domain of
GGA1 adaptor protein when associated with ARF1-GTP (Fig-
ure 5A), and the GAT-Arf1-EspG complex is striking in its
complementarity. In contrast, however, analysis of a recently
solved structure of ARF1 in complex with g-COP coat protein
(Yu et al., 2012) revealed a significant clash between EspG and
g-COP (Figure 5B), indicating that EspG would interfere with
COPI coat assembly at the Golgi. These observations suggest
that themolecular architecture of EspG stabilizes the GTP-active
state of ARF1 and, by protecting it from inactivation, effectively
promotes select downstream signaling events. Therefore, we
hypothesized that the pathogenic effects of EspG, and specif-
ically those that regulate microtubule-dependent processes,
are mediated by hyperstimulation of ARF1-GTP signaling.
To test this structural-based hypothesis, we first sought to
determine whether EspG stabilizes an ARF1/substrate complex
on host membranes. As shown in Figure 5C, EspG colocalized
with p58, implicating Golgi membranes as the primary site of
EspG function. Importantly, ARF1 was retained on p58-positive
membranes in the presence of EspG, but not in cells treated
with BFA (Figure S4A). These data are consistent with the
biochemical differences between EspG and BFA: EspG locks
ARF1 in the GTP active state, whereas BFA nucleates an inac-
tive ARF1-GDP/GEF complex in the cytosol. Then, to deter-
mine whether EspG association with Golgi membranes
requires ARF1-GTP Golgi localization, we assessed the sub-
cellular distribution of fluorescently labeled EspG in either
untreated cells or cells in which ARF1 was removed from mem-
branes by BFA treatment. This experiment showed that EspG
is cytosolic in the absence of membrane-bound ARF1, and
thus requires ARF1-GTP for association with Golgi remnants
(Figure 5D).
Next, we sought to determine directly whether membrane-
bound GTP-ARF1 could recruit endogenous substrates to
membrane bilayers when in complex with EspG. Initially, we
reconstituted this system on Golgi-mimetic liposomes using
purified recombinant proteins (Figure 5E). In control experi-
ments, the soluble GAT domain of GGA1, a prototypic ARF1 sub-
strate that bindswith high affinity, was selectively pulled down by
liposomes carrying GTP-loaded ARF1 (Figure 5F, lanes 3–6). In
agreement with our structural predictions, GGA1(GAT) was suc-
cessfully recruited into the EspG/ARF1 complex in an ARF1-
GTP-dependent manner (Figure 5F, lanes 7 and 8). Importantly,
EspG blocked the GAP-stimulated release of GGA1(GAT) from
liposomes, indicating that EspG effectively induces a constitu-
tively active form of ARF1 on membranes (Figure 5F, lanes 9
and 10). In cell-based studies, we also found that GGA1(GAT)
was recruited to fragmented Golgi membranes in cells microin-
jected with EspG, but not in cells where Golgi fragmentation
was induced by BFA (Figure S4B). As predicted by our structural
model, EspG interferedwith b-COP recruitment tomembranes in
a subset of cells (Figure S4C), but not in all cells (Selyunin et al.,
2011). It is possible that some coatomer assembly and vesicle
formation still occurred due to the considerable excess of
ARF1 molecules relative to EspG, as well as ARF-independent
COP recruitment to membranes (Deng et al., 2009; Ktistakis
et al., 1996). Taken together, these data strongly support a884 Cell Reports 6, 878–891, March 13, 2014 ª2014 The Authorsmechanism whereby EspG selectively protects specific down-
stream interactions of membrane-bound ARF1-GTP, which
combined with inactivation of Rab1 leads to Golgi disassembly
and inhibition of the GSP.
Identification of Downstream ARF1 Effectors
So far, our data indicate that EspG initiates an ARF1 GTPase
signaling cascade that is either directly or functionally linked to
microtubule-dependent membrane transport. Because neither
EspG nor ARF1 binds microtubules, the molecular mechanism
of EspG must therefore involve a host cellular component that
is (1) a specific effector for ARF1, (2) required for Golgi structural
maintenance, and (3) capable of inducing Golgi fragmentation
without affecting the microtubule network. Through extensive
analysis of published observations, we found two proteins that
met these criteria: GMAP-210 and Golgin-160. GMAP-210 is a
tubulin-binding protein that links small vesicles to organelle
membranes via a curvature-sensing N-terminal ArfGAP1 Lipid
Packing Sensor (ALPS) and a C-terminal GRIP-Related ARF
Binding (GRAB) domain that interacts with ARF1-GTP (Drin
et al., 2008; Rı´os et al., 2004). Golgin-160, on the other hand,
is found primarily on the cis-Golgi and is implicated in membrane
transport by connecting ARF1-GTP vesicles to dynein motors
(Yadav et al., 2012). Although the microtubule network remained
intact, depletion of either GMAP-210 or Golgin-160 disrupted the
Golgi morphology and resulted in a dispersed ministack
appearance of the Golgi (as visualized by transmission electron
microscopy), similar to the Golgi phenotype observed following
nocodazole treatment (Pernet-Gallay et al., 2002; Rı´os et al.,
2004; Yadav et al., 2009).
Because cellular disruption of GMAP-210 and Golgin-160
resulted in a well-defined multivesicular Golgi phenotype, we
used correlative light electron microscopy (CLEM) to determine
whether EspG would induce a similar Golgi morphology. The
cellular membrane fragments that correlated with the EGFP-
EspG fluorescent signal were organized in clusters of small ves-
icles (Figure 6A). These vesicles did not stochastically spread
throughout the cell, suggesting that the membranes may be
crosslinked through an EspG/ARF1-GTP-mediated protein com-
plex. Based on our observations that ARF1-binding by EspG is
sufficient to induce Golgi fragmentation, and EspG stabilizes
ARF1-GTP on membranes, we hypothesized that EspG most
likely blocks vesicular traffic through an ARF1-dependent tether
(i.e., GMAP-210 or Golgin-160; Figure 6B). Importantly, this
mechanism would explain the phenotypic similarity between
EspG and nocodazole treatment, as both restrict vesicular
movement beyond their budding site (Cole et al., 1996).
EspG Functions through GMAP-210 Signaling from the
ARF1 Complex
We now propose a model in which EspG promotes membrane
tethering by stabilizing ARF1-GTP on Golgi membranes, which
effectively increases the presence of tethering factors such as
GMAP-210 and inhibits vesicle fusion through Rab1-GAP
function. This model predicts that excessive expression of
GMAP-210 should induce a Golgi phenotype analogous to
EspG. To test this assumption, we examined the effects of
excess GMAP-210 on Golgi structure and function. Transient
Figure 5. EspG Functions Selectively through Downstream Interactions of Active ARF1
(A) Structural model of EspG bound to the ARF1/GGA1(GAT) complex, based on EspG/ARF1 (1PCR) and ARF1/GGA1(GAT) (1J2J and1O3X) X-ray structures.
(B) Structural model of EspG bound to the ARF1/g-COP complex, based on EspG/ARF1 (1PCR) and EspG/g,z-COP (3TJZ) structures. Insets show major steric
clashes, highlighted with dotted circles.
(C) Fluorescence micrographs show localization of GFP-EspG to p58-positive ERGIC membranes.
(D) Themembrane association of EspG is dependent onmembrane-bound ARF1. Fluorescently labeled EspG is localized to fragmented endomembranes during
microinjection, but is cytosolic when cells are pretreated with BFA.
(E) Experimental setup to examine (1) membrane recruitment of downstream effectors by ARF1 and (2) the susceptibility of the ARF1/effector complex to GAP-
mediated inactivation in the presence of EspG.
(F) Liposome pull-down experiments for the setup described in (D). EspG allows recruitment of the ARF1 effector tomembranes (1) and prevents its release due to
ARF1 inactivation by ArfGAP (2).
See also Figure S4.
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Figure 6. Disruption of the Golgi Architecture through ARF1-Dependent Membrane Tethering
(A) CLEM shows the vesicular ultrastructure of the Golgi after microinjection with EspG, which remains constrained to areas positive for EspG signal.
(B) Identification of golgin GMAP-210 as an ARF1-dependent membrane tether involved in the EspG mechanism of Golgi disassembly by linking vesicles to
membranes and preventing their transport.
(legend continued on next page)
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overexpression of the tethering protein induced severe Golgi
fragmentation and enlarged ERGIC (Figure S5A), as well as
accumulation of Golgi enzymes near p58-positive clusters (Fig-
ure S5B). Similar to what was observed for EspG, Golgi
disassembly by GMAP-210 overexpression was not due to
depolymerization of microtubules, which appeared intact (Fig-
ure S5C). We then wanted to confirm that inhibition of protein
transport due to excessive GMAP-210 tethering occurred in a
manner consistent with what we observed during EspGmicroin-
jection. Indeed, we found that Golgi-CAD was similarly trapped
near p58-positive clusters during an anterograde trafficking
assay (Figure S5D), and that overexpression of GMAP-210 also
protected NAGFP from BFA-induced redistribution into the ER
(Figure S5E). Finally, EM analysis of Golgi remnants during over-
expression of GMAP-210 showed a striking similarity to those
observed with EspG overexpression, displaying an extensive
accumulation of vesicles (Drin et al., 2008; Figure 6A).
At the core of our model, EspG protects membrane-bound
ARF1-GTP from inactivation by ARF GAP, increasing the selec-
tive accumulation of downstream ARF1-GTP substrates (i.e.,
GMAP-210) that promote vesicle tethering and inhibit membrane
fusion. This suggests that inhibition of membrane trafficking
associated with EspG is due to extensive ARF1-dependent
tethering events between membranes and vesicles (Figure 6E).
To more directly confirm that ARF1-dependent vesicle tethering
is sufficient to induce Golgi disassembly, we reengineered
GMAP210 and GGA1-GAT to model the proposed EspG viru-
lence system with a minimal set of interactions. Specifically,
we created a synthetic chimera protein (ALPS-GAT) consisting
of a GMAP-210 ALPS motif to bind small vesicles, and a soluble
GGA1-GAT domain, which associates with membranes only
when bound to active ARF1-GTP (Figure 6E). If our model were
correct, then the minimal ALPS-GAT chimera would functionally
mimic two aspects of the proposed EspG/ARF1/GMAP210
complex: (1) it would tether vesicles to Golgi membranes in an
ARF1-dependent manner, and (2) it would selectively promote
tethering while restricting other ARF-GTP signaling events,
such as COPI vesicle fission. In agreement with our model,
cellular expression of ALPS-GAT effectively disrupted Golgi
organization and function in a manner similar to that observed
for EspG (Figure 6F), but distinct from the phenotype we have re-
ported for BFA. Importantly, expression of either the ALPS motif
or GAT domains alone had no effect on Golgi morphology, con-
firming that disruption was directly dependent on tethering of
small vesicles to membrane-bound ARF1-GTP (Figure 6G).
Because in vitro assays to examine direct interactions
between GMAP-210 and ARF1 have proved difficult (Gillingham
et al., 2004), we used structural modeling to assess whether(C) Fluorescent micrographs showing the distribution of GMAP-210 relative to th
disassembly of the Golgi by EspG (arrowheads), in contrast to when ARF1 is rem
(D) Pull-down experiment showing the binding of EspG to GMAP-210/ARF1 com
(E) Cartoon schematic illustrating the design of an ARF1-dependent, membrane-t
domain of GGA1. Our model of EspG function predicts vesicle-to-membrane lin
(F) Overexpression of the ARF1-dependent, membrane-tethering chimera is suf
asterisk.
(G) Control experiments show no impact on Golgi organization due to overexpres
the absence of a direct tether.
See also Figure S5.EspG could bind to the ARF1/GMAP-210 complex on the mem-
brane. Using the structure of a related GRIP domain of golgin-
245 bound to Arl1 (Panic et al., 2003), we modeled the ARF1/
GMAP-210 interaction with EspG, and did not detect any
apparent steric clashes (Figure S5F). To test our hypothesis
more directly, we next looked at the presence of the ARF1/
GMAP-210 complex on fragmented Golgi remnants after EspG
microinjection. The C-terminal portion of GMAP-210 that con-
tains the ARF-binding motif (residues 1597–1843) localizes pri-
marily to the Golgi in an ARF1-dependent manner and does
not cause any apparent defects in Golgi morphology (Figure 6C).
As expected, BFA treatment abolished the association of
GMAP-210 (residues 1597–1843) with the membranes, in
contrast to EspG, whose microinjection retained membrane-
bound GMAP-210 despite fragmented Golgi (Figure 6C). Finally,
we also found that EspG associated with the ARF1/GMAP-210
complex in in vitro glutathione S-transferase (GST)-pull-down
experiments (Figure 6D). Together, these observations suggest
that the ARF1/GMAP-210 complex has a major role in the
EspG mechanism.
Thus, we predict that EspG binding to ARF1 drives excessive
membrane accumulation of specific ARF1 substrates, such as
GMAP-210, which consequently would lead to increased teth-
ering of vesicles or allow regulation of additional microtubule-
dependent processes (Figure 7A). Rab1-GAP activity prevents
vesicle fusion via Rab1-dependent machinery (Figure 7A, left),
which otherwise would require significantly higher levels of
EspG-induced tethering in order to outcompete and physically
restrict membrane fusion. Indeed, this phenomenon is reflected
in the attenuated induction of Golgi morphology by the EspG RQ
mutant (see Figure 4E). Moreover, ARF1 binding spatially re-
stricts the Rab1-GAP properties of EspG to a specific site, which
could be connected to the observed phenotypic differences
between EspG and Rab1-GAP transfection that led to a global
loss of Rab1 signaling. As expected, Rab1 did not fully dissociate
from fragmented Golgi in cells microinjected with EspG (Fig-
ure 7B). By preventing vesicle fusion and capturing vesicles in
close proximity to membranes, EspG effectively inhibits vesicle
transport at ERGIC and leads to Golgi disassembly.
DISCUSSION
In its active state, ARF1 recruits a wide variety of effectors to
membranes, including COPI coat proteins, lipid-modifying en-
zymes, and scaffolds for cytoskeletal anchoring (Donaldson
and Jackson, 2011). This makes it a prime target for a bacterial
protein that has evolved to regulate intracellular trafficking.
Although restricting GAP access allows EspG to control thee Golgi (GM130). GMAP-210 is retained on fragmented membranes following
oved from the membranes by BFA treatment.
plex.
ethering chimera using a vesicle-binding motif linked to an ARF1-GTP-binding
kage that is driven by the presence of GTP-ARF1 on membranes.
ficient to disrupt the Golgi architecture. Transfected cells are marked with an
sion of either a vesicle-binding motif or an ARF1-GTP-binding domain alone in
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Figure 7. EspG Inhibits Membrane Trafficking through Membrane Capture and Local Inactivation of Rab1
(A) Cartoon model of the EspG mechanism that relies on ARF1-dependent tethering and exclusion of Rab1-dependent vesicle fusion machinery.
(B) Fluorescent micrographs showing the localization of Rab1 relative to Golgi membranes in cells microinjected with EspG.activity state of ARF1, maintaining the GTPase in a constitutively
active confirmation through allosteric binding alone would be
inefficient when compared with molecules mimicking upstream
regulatory proteins, such as GEFs. Instead, the binding nature
of EspG suggests that it additionally acts as a selection mecha-888 Cell Reports 6, 878–891, March 13, 2014 ª2014 The Authorsnism that allows interaction of ARF1 with specific, but not all,
downstream substrates. Indeed, some endogenous ArfGEFs
have been shown to favor specific downstream signaling by
interacting with and preferentially recruiting a set of effectors
to ARF1 (Deng et al., 2009). Downstream substrate selectivity
combined with protection of ARF1 from GAP inactivation would
effectively allow EspG to inhibit some signaling pathways while
overstimulating others, thus expanding its function beyond that
of a simple activity modulator. Our proof-of-concept experi-
ments with Golgi mimetic liposomes support this idea by
showing that ARF1 can recruit its effectors to membranes
when bound by EspG, and that this complex remains resistant
to GAP treatment.
Interestingly, EspG displays a clear distinction from BFA-
or Rab1-GAP-associated trafficking phenotypes, as it neither in-
hibits ER export nor leads to accumulation of Golgi enzymes
in the ER. This suggests that regulatory coupling of host
signaling enzymes through scaffolding architecture, rather than
individual regulatory properties, drives the mechanism of
EspG. Targeting multiple host regulatory pathways through a
single effector molecule would allow bacteria to more efficiently
modulate complex host signaling networks and finely tune a
specific environment for their lifestyle. Indeed, an EspG homolog
from the intracellular pathogen S. flexneri, VirA, shares potent
GAP activity toward Rab1 and induces Golgi disassembly
(Dong et al., 2012). In contrast to EspG, however, VirA does
not interact with ARF1, and instead may coordinate the in-
activation of Rab1 with a different signaling pathway, further
supporting specific evolutionary adaptations of effector pro-
teins. Notably, Golgi disruption by S. flexneri can also be inde-
pendently induced by the recently characterized IpaJ effector,
which demyristoylates and inactivates ARF1 (Burnaevskiy
et al., 2013). It is therefore possible that IpaJ and VirA activities
complement each other to precisely control a range of trafficking
events under different conditions, further underlining the func-
tional need to selectively coordinate the regulation of individual
pathways.
Elucidating the exact functional role of an individual bacterial
effector molecule in an infection is difficult due to the large
number of proteins that are secreted by invading bacteria,
the variable number of bacteria that infect individual cells,
and the poorly understood order of secretion of effectors,
some of which may share host targets or mask activity. These
factors introduce wide variance and make it hard to connect a
distinct phenotype to any single molecule. By understanding
the molecular mechanism of an effector through focused
biochemical studies, such as the one presented here, we can
uncover its potential function within a host cell and obtain
direct insight into its role during an infection. Specifically,
EspG and VirA have been linked to microtubule cytoskeleton
phenotypes in cells infected by EHEC or S. flexneri, respec-
tively (Matsuzawa et al., 2004; Yoshida et al., 2002). Here,
we show that a distinct trafficking phenotype appears closely
related to that observed during microtubule disruption by
nocodazole, and that this connection could be linked to the
regulation of ARF and Rab GTPases. In addition, EHEC infec-
tion has been shown to inhibit cytokine secretion and decrease
transepithelial resistance (Dong et al., 2012; Philpott et al.,
1998). We present evidence that EspG potently inhibits GSP
by arresting membrane transport at ERGIC, which in turn in-
hibits cytokine secretion and delivery of adherence proteins
needed to maintain the tight junctions at the cell surface in
the intestinal lumen.Simultaneous regulation of select trafficking pathways, such
as antigen presentation by major histocompatibility complex
class I molecules, immunoglobulin M secretion, autophagosome
formation, and cytokine secretion, may afford bacterial patho-
gens the ability to avoid immune recognition specific to their
lifestyle. Indeed, EspG has been found to inhibit interleukin-8
secretion from HeLa cells during infection (Dong et al., 2012).
At the same time, the wide variety of bacteria with distinct life-
styles provide researchers with effective tools to better under-
stand the signaling interplay within complex regulatory systems
by studying the mechanisms of secreted scaffolding effector
proteins. Taken together, our data expose signaling-pathway
coupling via small molecular scaffolds as a regulatory hub of
intracellular trafficking, and describe an additional level of struc-
tural specificity that may have been previously overlooked.
EXPERIMENTAL PROCEDURES
Plasmids
The espG gene from EHEC O157:H7 was PCR cloned in frame into pEGFP-C2
(Clontech). For bacterial expression, 38 and 41 aa N-terminal deletions (resi-
dues 39–398 and 42–398) of EspG were PCR subcloned into pGEX-4T1
(GST-tag; Amersham) and pProEX-HTb (63His tag; Novagen) vectors. EspG
mutants were generated with QuikChange site-directed mutagenesis (Strata-
gene). Full-length ARF1 or the GTPase domain of ARF1 (ARF1D17) were PCR
subcloned into pcDNA3.1-mCherry or pGEX-4T1 and pProEX-HTb vectors,
respectively. The GTPase domain of Rab1 (residues 1–177) or full-length
ARF1 was subcloned from Rab1a cDNA (DNASU, Arizona State University)
into pGEX-4T3 or pEGFP-C1 vectors (Clontech). The GMAP-210 plasmid
was a kind gift from Bruno Antonny and Guillaume Drin (Institut de
Pharmacologie Mole´culaire et Cellulaire). All constructs were verified by
DNA sequencing.
Protein Purification for In Vitro Assays and Microinjection
Recombinant proteins were produced in BL21-DE3 E. coli strains. Protein
expression was induced with 0.4 mM isopropyl b-D-1-thiogalactopyranoside
for 16 hr at 18C. Bacterial pellets were lysed in either His buffer (100 mM
HEPES [pH 7.5], 300 mM NaCl) or GST buffer (TBS; 50 mM Tris [pH 7.5],
150 mM NaCl, 2 mM dithiothreitol) supplemented with protease inhibitors.
Proteins were purified with nickel agarose (QIAGEN) or glutathione Sepharose
(Amersham Biosciences). For microinjection, protein stocks were diluted with
TBS to the indicated concentrations.
In Vitro GST Pull-Downs
Recombinant GST-tagged proteins (10 mg) were immobilized to glutathione
Sepharose and incubated with 15 mg of 63His-tagged proteins for 1 hr at
4C. Samples were washed three times in TBS supplemented with 0.5% Triton
X-100. Proteins were eluted from beads with Laemmli sample buffer, sepa-
rated by SDS-PAGE, and analyzed by western blot. For nucleotide loading,
ARF1D17 was incubated in nucleotide loading buffer (40 mM HEPES,
150 mM NaCl, 2 mM EDTA, 10% glycerol) with 10 mM of either GDP or GTP
for 30 min at 37C, and then MgCl2 was added to 10 mM and the reaction
was transferred to ice after 15 min at 25C.
Cell Microinjection, Transfections, and Immunofluorescence
Microscopy
HeLa cells were microinjected with EspG proteins using a semiautomatic
InjectMan NI2 (Eppendorf) with a needle concentration of 25 mM unless stated
otherwise. Transfections were performed using XtremeGene 9 Transfection
Reagent (Roche) for 16–18 hr. Expression of NAGT I in NAGFP cells was stim-
ulated by the addition of 5 mM sodium butyrate (Sigma-Aldrich) to the media.
AMCA-EspG was produced using an NHS-AMCA labeling kit (Pierce). BFA
and nocodazole treatments were performed at 5 mg ml1 for 30 min and
30 mM for 2 hr, respectively. Cellular markers were detected using followingCell Reports 6, 878–891, March 13, 2014 ª2014 The Authors 889
antibodies: GM130 (BD TransductionLabs), ERGIC-53/p58 (Sigma-Aldrich),
TGN46 (Abcam), b-COP (EAGE, Joachim Seeman, UTSW), and a-tubulin
(Sigma-Aldrich).
Ligand-Inducible ER-to-Golgi Trafficking Assay
An inducible trafficking assay was developed by adapting the CAD of FKBP
F36M (Rivera et al., 2000) to control the secretory transport of a fluorescently
tagged b-1,4-galactosyltransferase signal sequence. See the Supplemental
Experimental Procedures for details.
Liposome Pull-Downs and Rab1 GAP Assay
Golgi mimetic liposomes were generated using lipid ratios reported by
Bremser et al. (1999). GTP loading of ARF1, liposome pull-down assays, and
GAP assays were conducted as previously described (Selyunin et al., 2011).
Briefly, ARF1-GTP-containing liposomes were incubated with GGA1(GAT) in
the absence or presence of EspG and ArfGAP, as shown in Figure 5, and bind-
ing was assessed by SDS-PAGE after sedimentation. In the Rab1-GAP assay,
5 mMGST-Rab1was incubatedwith 1 mMEspG (WT, RQ, and IPP) for 15min at
30C. See the Supplemental Experimental Procedures for additional details.
PAK Kinase Assay and IPA-3 Sensitivity
Kinase assays were performed as previously described (Selyunin et al., 2011).
In brief, GFP-PAK2 was purified from HEL293 cell lysates and preincubated
with myelin basic protein and the indicated amounts of IPA-3 (Sigma-Aldrich)
or DMSO in kinase buffer for 20 min at 4C. Cdc42-GTPgS or EspG (2 mM) was
then added and the reaction was preequilibrated for 10min at 30C. Reactions
were started by the addition of ATP with [32P]ATP and incubated for 15 min.
Finally, reactions were analyzed by SDS-PAGE and autoradiography, and
quantified using a scintillation counter.
CLEM
Microinjection andCLEMwere performed in amanner similar to that described
in Reddick and Alto (2012). Briefly, HeLa cells were cultured on gridded glass
coverslips (MatTek). EspG was fluorescently labeled using fluorescein isothio-
cyanate labeling (Pierce). Cells were fixed with 3% formaldehyde in PBS
30 min postinjection and a confocal Z stack was acquired on microinjected
cells using a Zeiss LSM5 Pascal confocal microscope. CLEM was performed
exactly as described in Reddick and Alto (2012).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.01.040.
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